For some of the sickest patients with COVID-19, treatment decisions have never been simple.
That is especially true when the patient already has kidney or liver disease.
Early in the pandemic, clinicians had legitimate concerns about using remdesivir for COVID-19 in people with severe kidney impairment. Liver disease raised another set of questions because remdesivir is metabolized in part through the liver and requires careful laboratory monitoring.
Now, new real world evidence is adding another piece to the picture.
A large 2026 study published in Clinical Infectious Diseases found that early remdesivir treatment was associated with a lower risk of death among adults hospitalized with COVID-19 who also had kidney or liver disease.
The findings are encouraging.
But they also need to be interpreted carefully.
This was an observational study, which means it can identify an association between treatment and survival but cannot prove that remdesivir alone caused the difference.
Still, for patients who have historically been harder to include in antiviral treatment decisions, the results matter.
Researchers examined U.S. medical claims and hospital data from 2021 through 2025.
They compared adults hospitalized with COVID-19 who received remdesivir early in their hospitalization with similar patients who did not receive the drug.
After matching patients to make the groups more comparable, the researchers analyzed 22,378 patients with kidney disease and 5,026 patients with liver disease.
The primary outcome was death from any cause within 28 days while hospitalized.
Among patients with kidney disease, early remdesivir treatment was associated with a 25 percent lower relative risk of 28-day in-hospital death.
Among patients with liver disease, the relative risk was approximately 24 percent lower.
The benefit was also seen among patients in both groups who required supplemental oxygen. Nearly 70 percent of patients in each cohort needed oxygen.
One finding was particularly notable.
Among patients with liver disease who were not receiving supplemental oxygen, early remdesivir was associated with a 49 percent reduction in the relative risk of death. The reduction among kidney disease patients who did not require oxygen was not statistically significant.
Those numbers deserve attention, but there is an important word here:
Relative.
A 25 percent reduction in relative risk does not mean that remdesivir prevents death in one out of every four patients. The absolute benefit depends on the patient's underlying risk of death.
That distinction matters when communicating medical research.
Patients with chronic kidney disease are already at higher risk of poor outcomes from serious infections, including COVID-19.
Yet early in the pandemic, some patients with advanced kidney disease were excluded from remdesivir treatment or clinical trials.
Part of the concern involved the drug's carrier, sulfobutylether-beta-cyclodextrin, or SBECD, which can accumulate when kidney function is severely impaired.
Our understanding has changed.
The FDA expanded approval of remdesivir in 2023 to include patients with severe renal impairment, including patients receiving dialysis. Current guidance does not require dose adjustment based on kidney function.
Randomized evidence has also provided some reassurance.
The REDPINE trial specifically evaluated hospitalized COVID-19 patients with severe kidney impairment. It was not large enough to establish a clear mortality benefit, but investigators found remdesivir to be safe in patients with severe renal impairment.
A later systematic review and meta-analysis also found no significant increase in hepatic complications among severely renally impaired patients treated with remdesivir, although the evidence across studies remains complex.
The newer 2026 study adds something different.
Instead of focusing mainly on safety, it asks whether early treatment might actually improve survival in this high risk population.
Liver disease creates a different challenge.
Remdesivir undergoes metabolism involving the liver, so clinicians need to pay attention to liver function before and during treatment.
Patients in the new study included people with conditions such as cirrhosis, liver failure, liver injury, and noninfectious hepatitis.
The observed survival difference is therefore important.
Historically, clinicians may be understandably hesitant when prescribing medications to patients who already have significant liver dysfunction.
But avoiding treatment also has consequences.
A patient with advanced liver disease who develops severe COVID-19 may already have a high baseline risk of complications and death. The question is not simply whether a drug carries risk.
The better clinical question is:
Does the potential benefit outweigh that risk for this particular patient?
That is where individual assessment remains essential.
Remdesivir should not be viewed as automatically appropriate for every hospitalized patient with liver disease. Liver laboratory testing and clinical monitoring remain important.
One theme continues to appear across antiviral research.
Timing matters.
Antiviral drugs work by interfering with viral replication. Their potential benefit is therefore generally greater when treatment begins earlier in the disease process rather than after the illness has become dominated by severe inflammation and organ damage.
The 2026 study examined early remdesivir initiation, with treatment beginning within the first two days of hospitalization in the underlying analysis.
That fits with broader guidance around COVID-19 antiviral therapy.
The Infectious Diseases Society of America's 2025 guideline update notes that remdesivir provides the greatest benefit when used early in the disease course for appropriate high risk patients.
For clinicians, this creates a practical issue.
Identifying the right patient is important.
Identifying that patient quickly may be just as important.
This is where medical headlines require some caution.
The study was retrospective.
Researchers used propensity score matching to make patients receiving remdesivir more comparable with those who did not receive it. That is a useful statistical approach, but it cannot account for every difference between the groups.
There may still be factors that influenced both the decision to prescribe remdesivir and a patient's likelihood of survival.
For example, treatment decisions may vary based on hospital practices, clinician judgment, illness severity, available resources, or other factors that are difficult to capture completely in claims data.
So the safest interpretation is not:
Remdesivir reduces mortality by exactly 25 percent in kidney disease.
It is:
Early remdesivir use was associated with lower mortality in a large real world population of hospitalized COVID-19 patients with kidney or liver disease.
That is still a meaningful finding.
It simply reflects what this type of research can actually tell us.
It is also worth noting that several authors of the study are affiliated with Gilead Sciences, the manufacturer of remdesivir. Industry involvement does not invalidate the results, but funding and author relationships should always be considered alongside study design and independent evidence when interpreting pharmaceutical research.
Research does not end when a paper is published.
What happens when the evidence reaches hospitals, clinics, physicians, pharmacists, and patients matters just as much.
This is where a strong healthcare community can have real value.
A nephrologist may view new remdesivir data differently from an infectious disease physician. A hepatologist may focus on liver monitoring. A hospitalist may be thinking about when treatment should begin and which hospitalized patients are most likely to benefit.
Pharmacists bring another perspective.
So do nurses and researchers.
When healthcare professionals can discuss emerging evidence together, the conversation becomes more useful than simply reading a headline saying a drug “cuts the risk of death.”
Healthcare communities can help clinicians question the study design, understand relative versus absolute risk, compare findings with their own clinical experience, and identify where more research is still needed.
Platforms such as MedSocially can support these conversations by giving physicians, nurses, researchers, pharmacists, and other healthcare professionals a place to discuss new medical evidence and what it may mean in everyday practice.
That type of professional discussion matters.
Medical evidence changes.
Clinical interpretation should change with it.
The latest research does not suddenly make remdesivir a simple treatment decision.
It does something more useful.
It gives clinicians additional evidence that kidney or liver disease alone should not automatically remove remdesivir from consideration when treating an appropriate patient hospitalized with COVID-19.
For kidney disease, the safety picture has become clearer over the past several years.
For liver disease, careful monitoring remains important.
For both groups, timing, disease severity, oxygen requirements, other medications, underlying health conditions, and individual risk still matter.
And the new mortality findings need confirmation through continued research.
That is how medicine moves forward.
Not with one dramatic headline.
With evidence accumulating piece by piece.
The question for clinicians is no longer simply:
“Does this patient have kidney or liver disease?”
It is:
“Given this patient's condition, severity of COVID-19, treatment timing, and individual risks, could early antiviral therapy improve the outcome?”
The latest remdesivir research gives clinicians more information to help answer that question.
And for some of our highest risk patients, that information could matter.
